IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

GIANNI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 12.436
AS - Asia 9.715
NA - Nord America 8.345
SA - Sud America 1.054
AF - Africa 165
OC - Oceania 25
Continente sconosciuto - Info sul continente non disponibili 5
Totale 31.745
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.033
GB - Regno Unito 4.849
CN - Cina 3.009
SG - Singapore 2.672
DE - Germania 1.746
RU - Federazione Russa 1.552
IT - Italia 1.184
SE - Svezia 993
HK - Hong Kong 839
VN - Vietnam 792
TR - Turchia 769
BR - Brasile 765
KR - Corea 473
IE - Irlanda 464
FR - Francia 372
IN - India 355
NL - Olanda 348
UA - Ucraina 327
FI - Finlandia 281
BD - Bangladesh 258
EU - Europa 225
CA - Canada 212
JP - Giappone 147
PL - Polonia 123
ID - Indonesia 97
CO - Colombia 91
AR - Argentina 75
CI - Costa d'Avorio 53
IQ - Iraq 51
MX - Messico 45
TH - Thailandia 44
EC - Ecuador 43
ES - Italia 35
BE - Belgio 34
ZA - Sudafrica 32
AT - Austria 24
VE - Venezuela 24
IL - Israele 23
SA - Arabia Saudita 23
AU - Australia 22
DK - Danimarca 18
LB - Libano 18
UZ - Uzbekistan 18
CL - Cile 17
KE - Kenya 16
PY - Paraguay 16
PE - Perù 15
MY - Malesia 14
BG - Bulgaria 12
JM - Giamaica 12
PH - Filippine 12
TW - Taiwan 12
PK - Pakistan 11
TN - Tunisia 11
CZ - Repubblica Ceca 10
MA - Marocco 10
ET - Etiopia 9
GR - Grecia 9
CH - Svizzera 8
EG - Egitto 8
JO - Giordania 8
PS - Palestinian Territory 8
TT - Trinidad e Tobago 8
AZ - Azerbaigian 7
RO - Romania 7
AE - Emirati Arabi Uniti 6
CR - Costa Rica 6
IR - Iran 6
KZ - Kazakistan 6
NG - Nigeria 6
NO - Norvegia 6
NP - Nepal 6
DZ - Algeria 5
LT - Lituania 5
OM - Oman 5
BO - Bolivia 4
GE - Georgia 4
GT - Guatemala 4
MN - Mongolia 4
PA - Panama 4
PT - Portogallo 4
RS - Serbia 4
SK - Slovacchia (Repubblica Slovacca) 4
UY - Uruguay 4
BB - Barbados 3
BH - Bahrain 3
BZ - Belize 3
DO - Repubblica Dominicana 3
GA - Gabon 3
HU - Ungheria 3
LK - Sri Lanka 3
MD - Moldavia 3
SY - Repubblica araba siriana 3
AM - Armenia 2
BY - Bielorussia 2
HN - Honduras 2
KG - Kirghizistan 2
LU - Lussemburgo 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
Totale 31.932
Salva come PNG Salva come JPEG
Città #
Southend 4.609
Singapore 1.428
Hong Kong 801
Seattle 782
Ashburn 614
Beijing 566
Princeton 526
Chandler 511
San Jose 502
Frankfurt am Main 498
Dublin 461
Wilmington 442
Milan 379
Redmond 346
Hanover 318
Dallas 315
Council Bluffs 292
Jacksonville 249
Mountain View 242
Sakarya 226
Lauterbourg 223
Nanjing 212
Ho Chi Minh City 201
Dearborn 181
Bengaluru 177
Los Angeles 177
Guangzhou 174
Buffalo 150
Santa Clara 150
Des Moines 145
Hanoi 143
Dong Ket 132
Ann Arbor 128
Serra 119
Fairfield 116
Shanghai 114
Moscow 111
Woodbridge 109
Warsaw 108
New York 104
Toronto 103
Somerville 102
Berlin 97
Hefei 94
Columbus 77
Nanchang 75
Bogotá 74
Andover 72
Shenyang 72
Tianjin 70
Regensburg 68
Tokyo 67
The Dalles 66
Houston 65
Jinan 63
Ottawa 62
Boardman 59
São Paulo 58
Phoenix 55
Cangzhou 54
Abidjan 52
Changsha 48
Chicago 46
Falls Church 46
Hangzhou 45
Munich 44
Shenzhen 44
Hebei 43
Redwood City 43
Kunming 33
Jiaxing 32
Seoul 32
Rome 30
Bitonto 28
Helsinki 28
Nuremberg 28
Zhengzhou 28
Brussels 27
Haiphong 27
San Diego 27
Baghdad 26
Pisa 26
Jakarta 24
Da Nang 23
Ningbo 23
Rio de Janeiro 23
Fuzhou 21
Bangkok 19
Washington 19
Wuhan 19
Cambridge 18
Cupertino 18
Curitiba 18
Haikou 17
Johannesburg 16
Orem 16
Sunnyvale 16
Brasília 15
Dhaka 15
Kiez 15
Totale 19.652
Salva come PNG Salva come JPEG
Nome #
HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma 717
Topical prophylaxis of conjunctivitis induced by high-dose cytosine arabinoside 671
Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue 314
Dendritic cell viability is decreased after phagocytosis of apoptotic tumor cells induced by staurosporine or vaccinia virus infection 273
Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells 264
Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells 251
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned 236
Targeting TRAIL Receptors with Genetically-Engineered CD34+ Hematopoietic Stem Cells 235
High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion : an outpatient preparative regimen for autologous hematopoietic cell transplantation 228
Interferon γ enhances the anti-myeloma activity of the fully human anti-HLA-DR monoclonal antibody 1D09C3 225
Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas : pre-transplant disease status and histotype heavily influence outcome 217
The anti-HLA-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing NOD/SCID mice 214
CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice 212
The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy 211
Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34+-derived dendritic cell vaccination: a phase I trial in metastatic melanoma 210
Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers 209
Age- and irradiation-associated loss of bone marrow hematopoietic function in mice is reversed by recombinant human growth hormone (rhGH) 209
Human CD34+ cells engineered to express membrane-bound tumor necrosis factor–related apoptosis-inducing ligand target both tumor cells and tumor vasculature 209
Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34+ cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial 206
Antitumor activity of human CD34+ cells expressing membrane-bound tumor necrosis factor-related apoptosis-inducing ligand (mTRAIL) 206
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma 204
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial 204
Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) 203
Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term 203
Long-term outcome of ric-allo SCT for myeloma 202
Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib : the role of circulating interleukin-8 to enhance the prognostic accuracy 201
Use of recombinant hematopoietic growth factors after chemotherapy and high-dose chemo-radiotherapy 199
Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes 197
Skewed T cell differentiation in indolent non-Hodgkin's lymphoma patients reversed by ex-vivo T cell culture with {gamma}c-cytokines 194
Targeting Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Agonistic Receptors for Cancer Therapy 193
Anticancer cell therapy with TRAIL-armed CD34+ progenitor cells 193
Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab : a 20-year retrospective follow-up study in patients with lymphoma 192
Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts 191
Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis 190
High-dose sequential chemotherapy and in vivo Rituximab-purged stem cell autografting in mantle cell lymphoma : a 10-year update of the R-HDS regimen 190
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 187
CLIPI : a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11) 186
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell support for high-risk primary breast cancer: results from the Italian national registry 186
Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin’s lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin®) 184
A computational approach to compare microvessel distributions in tumors following antiangiogenic treatments 184
Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation 183
Antitumor activity of adenovirally transduced CD34+ cells expressing membrane-bound TRAIL 183
In vivo T-cell immune response against anaplastic lymphoma kinase in patients with anaplastic large cell lymphomas 181
Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma 180
Persistent CD30 expression by embryonal carcinoma in the treatment time course: prognostic significance of a worthwhile target for personalized treatment 180
Analysis of human embryonic hemoglobins and globins by isoelectric focusing 179
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis : the superior disease control of R-HDS does not translate into an overall survival advantage 178
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen) 176
Mobilization of primitive and committed hematopoietic progenitors in nonhuman primates treated with Defibrotide and recombinant human granulocyte colony-stimulating factor 176
In Vitro and In Vivo Anti-Lymphoma Activity of the Anti-HLA-DR Monoclonal Antibody 1D09C3 175
The use of GM-CSF and peripheral blood stem cells (PBSC) minimises haematological toxicity following a myeloablative course of chemo-radiotherapy 175
G gamma and A gamma globin chains separation and quantitation by isoelectric focusing 175
Bone marrow transplantation for lymphoma CR1 172
Reduced intensity allogeneic stem cell transplantation is an effective salvage treatment for relapsed non-Hodgkin’s and Hodgkin’s lymphomas 172
HSP105 inhibition hampers the growth of human aggressive B-cell non-Hodgkin lymphoma by counteracting key oncogenic pathways 171
Constitutive localization of DR4 in lipid rafts is mandatory for TRAIL-induced apoptosis in B-cell hematologic malignancies 171
Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases 171
Placental Growth Factor-1 Potentiates Hematopoietic Progenitor Cell Mobilization Induced by Granulocyte Colony-Stimulating Factor in Mice and Nonhuman Primates 169
Antitumor Activity of Human CD34+ Cells Expressing Membrane-Bound Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (mTRAIL) 169
Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34+ cells 168
Highly efficient gene transfer into mobilized CD34+ hematopoietic cells using serotype-5 adenoviral vectors and BoosterExpress™ Reagent 167
Biology and clinical applications of marrow mesenchymal stem cells 165
Early chemotherapy intensification with escalated beacopp in patients with advanced-stage hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two abvd cycles : long-term results of the GITIL/FIL HD 0607 trial 164
Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses 163
Cellular and molecular mechanisms of the human embryonic leads to fetal hemoglobin switch 162
Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venocclusive disease of the liver 162
Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy : possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results. 161
Primary Plasma Cells Expressing CD52 Are Efficiently Targeted In Vivo by Alemtuzumab 161
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma : the Italian experience and results of its use in daily clinical practice outside clinical trials 161
Corrigendum: Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue (Annals of Oncology (2018) 29 (2363-2370) DOI: 10.1093/annonc/mdy450) 161
Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis 158
Activity of a monoclonal antibody-saporin-6 conjugate against B-lymphoma cells 158
Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type 157
High response rate and manageable toxicity with an intensive, short-term chemotherapy program for Burkitt’s lymphoma in adults 157
Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis 155
The HLA-DR-specific monoclonal antibody 1D09C3 exerts a potent antitumor activity on malignant lymphoid cells both in vitro and in vivo 155
Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunological responses in indolent B-cell lymphoma patients with relapsed and measurable disease : a pilot study 154
The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells 153
Amantadine potentiates T lymphocyte killing by an anti-pan-T cell (CD5) ricin A-chain immunotoxin 152
A gene controlling fetal hemoglobin expression in adults is not linked to the non-alpha globin cluster 151
Adenovirus vectors for gene transduction into mobilized blood CD34+ cells 146
Detection of minimal residual disease in hematopoietic progenitor cell harvests : lack of predictive value of peripheral blood and bone marrow analysis in mantle cell and indolent lymphoma 145
Role of recombinant human granulocyte-macrophage colony stimulating factor for large scale collection of peripheral blood stem cells for autologous transplantation 145
MALT lymphoma and Kaposi Sarcoma in an HIV-negative patient 144
Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia 144
High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma : a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence 143
HSP105 inhibition counteracts key oncogenic pathways and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma 142
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies 141
Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting : evidence of marked differences in outcome between patients with age-adjusted International Prognostic Index scores 2 and 3 140
Human globin chain separation by isoelectric focusing 139
An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions 139
Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma : associations with presenting features, serum interleukin 10 levels, and clinical outcome 138
Radioimmunotherapy and secondary leukemia : a case report 138
Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli 135
Conditions influencing the expansion of the circulating hemopoietic progenitor cell compartment 135
Brentuximab Vedotin in CD30-Positive Lymphomas : a SIE, SIES, and GITMO Position Paper 134
CD34-positive cells: biology and clinical relevance 133
Successful second autologous engraftment after long duration storage of hematopoietic stem cells 133
Early hematopoietic zinc finger protein (EHZF), the human homolog to mouse Evi3, is highly expressed in primitive human hematopoietic cells 131
A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies 131
Totale 18.857
Salva come PNG Salva come JPEG
Categoria #
all - tutte 88.058
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 88.058
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021964 0 0 0 0 0 0 0 0 0 0 731 233
2021/20222.624 191 140 139 149 402 176 169 117 214 299 188 440
2022/20232.281 404 227 187 190 205 619 43 114 176 21 55 40
2023/20241.503 22 104 61 66 284 90 103 121 47 87 247 271
2024/20253.515 217 371 107 338 280 117 93 433 217 279 314 749
2025/20268.675 755 484 1.071 868 916 696 890 797 1.033 522 643 0
Totale 33.619